Patients with depression who used tablet computers to complete brief positive psychology exercises online several times a week scored lower on depressive symptoms and reported that they felt better able to cope with their kidney disease by the end of the five-week pilot study, led by University of Illinois social work professor Rosalba Hernandez.
Recent Emory research sheds light on precursor B cells and their role in the development of systemic lupus erythematosus/SLE.
Scientists have developed a successful method to make truly personalised predictions of future disease outcomes for patients with certain types of chronic blood cancers. Wellcome Sanger Institute researchers and collaborators combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms. Published in the New England Journal of Medicine, the research identified eight different genetic subgroups of the disease and could lead to personalized medicine for patients with these blood cancers.
Pediatric researchers studying the life-threatening blood disorder Fanconi anemia have devised a method to block the abnormal biological signals that drive the disease. This proof-of-concept finding in animals and stem cells from human cord blood may lay the foundation for better treatments for children with the rare, frequently fatal disease.
Atherosclerosis is regarded as a chronic inflammatory disease associated with changes in the innate immune system functioning and cytokine disturbances. In this study, we explored localization of a pro-inflammatory cytokine, tumor necrosis factor-α (TNFα), and anti-inflammatory chemokine, C-C motif chemokine ligand 18 (CCL18), in the arterial wall of human aorta.
For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood. The DUO trial studied duvelisib versus ofatumumab, an approved standard-of-care chemotherapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). According to the study, duvelisib extended PFS from a median of 9.9 months on ofatumumab to 13.3 months.
Physicians who specialize in a devastating and aggressive immune disorder called hemophagocytic lymphohistiocytosis (HLH) report in a new study that extra care should be taken to ensure an HLH diagnosis doesn't obscure possible underlying cancers. They caution in the journal Pediatric Blood & Cancer that expediting HLH treatment may miss underlying malignancies that could end up being fatal to the patient.
Russian scientists have carried out tests to compare the process of blood coagulation in adults and newborns and discovered that the latter face an increased risk of thrombosis. The researchers also compared this process in infants carried to term and in preterm babies. The work was carried out as part of a project funded by the Presidential Program of Research Projects of the Russian Science Foundation (RSF), with the results being published in Pediatric Research.
A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia actively undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.
Researchers at Mount Sinai have discovered that an antimicrobial protein found in the gut can stave off a common and highly lethal side effect of bone marrow transplants, according to a study published in the Journal of Clinical Investigation in September.